The government's medicines advisory body meets critics today to debate changes to the way it decides whether the National Health Service pays for costly new drugs.

Professor Sir Ian Kennedy, who is chairing a review triggered by attacks on the National Institute for Health and Clinical Excellence, will hear complaints from the pharmaceutical industry, patients and academics that it it does not take sufficient account of innovation.